If you only read the press—of which there was plenty--about Jazz Pharmaceuticals Inc. 's $250 million private financing, [See Deal] all you'd probably have learned is that it was the biggest series B round ever and that the deal represented the debut of Kohlberg Kravis Roberts & Co.—best known for mega-LBOs--into the very unleveraged world of biopharmaceuticals.
And you would have missed the whole point. Jazz represents a fundamentally different business model for biopharmaceutical investing and companies:...







